The results from studies on the sensitivity of conventional therapeutic drugs have demonstrated that the reinstatement of CLDN6 expression in breast cancer cells increases chemoresistance to Adriamycin, an anticancer medication that is frequently used to treat breast cancer by activating the AF-6/ERK signaling pathway and upregulating cancer stem cell properties (135, 136). Here, CLDN6 is linked to cancer.